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Abstract
Background: Bifurcation PCI is associated with a lower rate of procedural success,
especially in multivessel disease patients. We aimed to determine the impact of bifur-
cation treatment on 2-years clinical outcomes when a state-of-the-art PCI strategy
(heart team decision-making using the SYNTAX score II, physiology guided coronary
stenosis assessment, thin strut bioresorbable polymer drug-eluting stent, and intra-
vascular ultrasound guidance) is followed.
Methods: Three-vessel disease patients enrolled in the SYNTAX II trial (n = 454) were
categorized in patients with (a) ≥1 treated bifurcation (n = 126), and (b) without bifurca-
tion (n = 281). The primary endpoint was the occurrence of major adverse cardio and
cerebrovascular events (MACCE—a composite of all-cause death, stroke, any myocar-
dial infarction, or any revascularization) at 2 years. Secondary endpoints were the
occurrence of target lesion failure (TLF) defined as cardiac death, target-vessel myocar-
dial infarction and ischemia-driven target lesion revascularization, and the individual
components of the composite primary endpoint, as well as stent thrombosis.
Results: A total of 145 bifurcation were treated in 126 patients. At 2 years, MACCE
occurred in 75/407 patients (20.7% for bifurcation versus 17.5% for nonbifurcation,
hazard ratio [HR] of 1.28, CI95% 0.78–2.08, p = .32). TLF presented a trend toward
higher occurrence in bifurcation (16.8% vs. 10.8%, HR 1.75, CI95% 0.99–3.09,
Abbreviations: CABG, coronary artery bypass graft; FFR, fractional flow reserve; GDMT,
Guideline-directed medical therapy; IDR, ischemia-driven revascularization; iFR,
instantaneous wave-free ratio; IVUS, intravascular ultrasound; MACCE, major adverse
cardiovascular or cerebrovascular events; MI, myocardial infarction; OCT, optical coherence
tomography; PCI, percutaneous coronary intervention; QCA, quantitative coronary
angiography; TLF, target lesion failure.
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p = .053). Definite stent thrombosis did not differ at 2-year between groups (0.8%
for the bifurcation vs. 0.7% for the nonbifurcation, p = .92).
Conclusion: Bifurcation treatment in patients with three-vessel disease undergoing
state-of-the-art PCI had similar event rate of MACCE but was associated with a trend
toward higher incidence of TLF compared with nonbifurcation lesions.
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1 | INTRODUCTION
Bifurcation lesions are involved in up to 20% of percutaneous coro-
nary interventions (PCI),1 and that number can be higher in multi-
vessel diseased patients.2 Bifurcation treatment poses great technical
difficulties and a variety of strategies is offered to the interventional
cardiologist. Historically, PCI of bifurcation lesions are known to be
associated with poorer procedural success, thus with worse clinical
outcomes when compared with PCI of nonbifurcation lesions.3,4
Extensive debate on the best approach for bifurcation percutane-
ous treatment is still ongoing.3,5–8 Multiple trials have tested mostly
the approach of a provisional stent techniques versus the upfront
treatment with two stents. However, most trials do not use physiolog-
ical assessment of the lesions and none of these trials combine the
guidance by physiology with image guidance of the intervention
(e.g., intravascular ultrasound, IVUS or optical coherence tomogra-
phy, OCT).
SYNTAX II is a study on multivessel disease patients, without
involvement of left main stem, with the use of the so-called state-of-
the-art PCI (i.e., intervention guided by IVUS and instantaneous wave-
free ratio—iFR, chronic total occlusions (CTOs), and bifurcation lesions
performed preferably by specialists and using newer generation drug
eluting stents). We sought to investigate the clinical outcomes of the
state-of-the-art PCI for bifurcation lesions, compared with PCI for
nonbifurcation lesions in three-vessel disease patients of the SYNTAX
II study.
2 | METHODS
2.1 | Study population
This is a posthoc analysis of the SYNTAX II study. SYNTAX II is an all-
comers, multicenter, open label, single-arm study which enrolled
454 patients with three-vessel coronary artery disease without left
main involvement who were candidates for revascularization. The rec-
ruiting center's heart teams screened the patients who had to have a
SYNTAX score II with an equipoise between CABG and PCI.9 Details
of the study are published elsewhere.2
For the purpose of this analysis patients were categorized in two
groups: (a) those with the presence of at least one bifurcation lesion
that was considered physiologically significant and was treated and
(b) patients without any bifurcation lesion diagnosed with visual
assessment of coronary angiography. Forty patients had bifurcation
lesions but not treated after physiological assessment, thus these
patients were not included in the analysis. Bifurcation lesion was
defined as a stenosis that occurs at, or adjacent to a significant divi-
sion of a major epicardial coronary artery. Main vessel and branch
must be at least 1.5 mm of size to be accounted for in the
analyses.2,10
2.2 | State-of-the-art PCI
The approach used in these patients combined physiologically guided
intervention, a mandatory post-PCI intravascular ultrasound (IVUS)
assessment of adequate stent expansion and apposition,11 and the
use of a novel thin strut (70 μm, with abluminal biodegradable poly-
mer coating stent—SYNERGY, Boston Scientific). Also, bifurcation
treatment followed the consensus of the European Bifurcation Club
(EBC)10 and CTO PCI was preferably performed by a dedicated CTO
operator. Guideline-directed medical therapy (GDMT) and strict con-
trol of LDL-cholesterol were also advocated during the follow-up of
the trial.
Physiology assessment of lesions intended to treat was performed
with a hybrid coronary physiology approach using iFR and fractional
flow reserve (FFR)—according to the flowchart in Figure 1. The lesion
was treated if considered functionally significant (iFR <0.86 or iFR
between 0.86 and 0.93 with an FFR <0.80). Decision regarding the
strategy and technique for bifurcation intervention was left to the dis-
cretion of the operator with a protocoled recommendation derived
from the EBC consensus. Since the patients had 3-vessel disease, the
procedures could also be done in a staged fashion.
2.3 | Study endpoints and definitions
The primary endpoint for the present analysis is the composite of
MACCE, or patient oriented composite endpoint: a composite of
all-cause death, stroke, any myocardial infarction (MI), or any revascu-
larization, at 2 years.12 Secondary endpoints comprised the device
oriented composite endpoint of target lesion failure (TLF), the individ-
ual nonhierarchical components of the primary endpoint, as well as
definite stent thrombosis, at 2 years. TLF is defined as the composite
of cardiac death, target vessel MI, and ischemia-driven
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revascularization. MI was defined according to the Society for Cardio-
vascular Angiography and Interventions (SCAI) consensus for peri-
procedural MI (when ≤48 hr) or to the Third Universal Definition for
MI (if >48 hr after the index procedure).13,14 Stent thrombosis was
defined in accordance with the Academic Research Consortium.15 All
adverse events were adjudicated by an independent clinical event
committee. All patients signed informed consent. Follow-up is ongo-
ing through 5 years, and the present report is complete in all patients
through 2 years. Quantitative coronary angiography (QCA) analysis
for assessment of bifurcation lesions was performed in an indepen-
dent angiographic core laboratory (Cardialysis, Rotterdam, the
Netherlands).16
2.4 | Statistical analysis
Continuous data are presented as mean ± standard deviation of the
mean or as median and interquartile range according to data distribu-
tion. Comparisons were performed using Student's t-test or Mann–
Whitney U test whenever appropriate. Categorical data were com-
pared with the Chi-square test or Fisher's exact test and are shown as
absolute number and percentages. Event rates were based on
Kaplan–Meier estimates, and plotted in time-to-first-event analyses
and compared with Cox proportional hazards model. The confounders
used for adjustment of the hazard ratio calculations were: age, sex,
diabetes, smoking status, hyperlipidemia, and hypertension. Two-
sided α error of .05 was considered to determine statistical signifi-
cance. All statistical analyses were performed with the use of SAS
software, version 9.4 (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | Baseline and procedural characteristics
From the 454 patients included in the study, 447 had PCI performed.
One hundred and twenty-six (126) patients had at least one
bifurcation treated comprising a total of 145 treated bifurcations, and
281 patients had no bifurcation lesions diagnosed with visual assess-
ment of the angiography (Figure 2). Baseline characteristics were bal-
anced between the groups, except for the presence of hyperlipidemia,
higher in the treated bifurcation group (Table 1).
By angiographic core laboratory analysis, patients in the treated
bifurcations group had greater anatomic complexity, as reflected by a
higher anatomic SYNTAX score. On the other hand, SYNTAX score II
along with its 4-year mortality prediction for PCI were comparable
between the two groups. (Table 2). The number of lesions undergoing
physiological assessment were the same between the groups, but a
greater number of coronary segments were assessed and treated in
the bifurcation group (Table 2). Overall, the number and length of
stents were higher in the bifurcation group (Table 2). Intravascular
ultrasound data showed that malaposition was low and comparable
between groups (6.0% vs. 6.3%)—Table 2. Also, worthy of mentioning
is that postdilatation performed based on IVUS findings was signifi-
cantly higher in the patients with a treated bifurcation lesion (46%
vs. 36.8%, p = .004, respectively). Visually assessed Medina 1,1,1
occurred in 54 of the 145 bifurcations (37.2%). Final kissing balloon
F IGURE 1 SYNTAX II flowchart
for the physiological assessment of all
lesions intended to be treated [Color
figure can be viewed at
wileyonlinelibrary.com]
F IGURE 2 Patient flowchart
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was performed in 41.7% of bifurcations. Two-stent techniques in at
least one of the bifurcation lesions per patient were used in
63 patients (50%). The most common approaches for treating bifurca-
tion according to the MADS classification were: MB stenting across
SB 27.6%, PM stenting with or without KB 22.1% and Culotte 6.9%
(Data S1—Table S1). Core laboratory QCA analysis of the bifurcation
lesions are presented in Data S1—Table S2.
3.2 | Clinical outcomes
At 2 years the primary composite endpoint (MACCE) occurred in
75 patients (20.7% for treated bifurcation vs. 17.5%, hazard ratio
[HR] of 1.28, CI95% 0.78–2.08, p = .32). Patients with treated bifurca-
tion presented a trend toward higher occurrence of TLF at 2 years
(16.8% vs. 10.8%, HR 1.75, CI95% 0.99–3.09, p = .053), compared
with those without any bifurcation. With the exception of stroke
(1.6% vs. 2.2%, HR 0.38, CI 95% 0.05–3.20, p = .37) and revasculariza-
tion (8.2% vs. 10.9%, HR 0.86, CI 95% 0.41–1.78, p = .68); all cause
death (5.6% vs. 1.8%, HR 2.78, CI 95% 0.83–9.37, p = .10), and MI
(8.0% vs. 4.3%, HR 2.09, CI 95% 0.89–4.94, p = .09) contributed to
increase MACCE in the treated bifurcation group compared with
nonbifurcation, respectively (Figure 3). Definite stent thrombosis did
not differ at 2-year between groups (0.8% for treated bifurcation
vs. 0.7% for nonbifurcation, p = .92). Bifurcation treatment with two
or more stents had comparable MACCE, TLF, and stent thrombosis to
treatment with only one stent (Figure 4). A posthoc power calculation
for the primary endpoint taken into account the event rates and two-
sided alpha of .05 resulted in a low power of 9.97%. The sample size
needed for reaching a difference in the primary endpoint with an 80%
power would be of 5,630 three-vessel diseased patients.
4 | DISCUSSION
The main finding of this study is that in patients with three-vessel dis-
ease that are candidates for both percutaneous or surgical coronary
revascularization, the presence of bifurcation lesions that were
treated using the state-of-the-art PCI did not impact on the occur-
rence of the composite endpoint of death, MI, stroke, or any revascu-
larization, compared with percutaneous treatment of nonbifurcation
lesions. However, we showed that, in this population, there was a
trend toward increasing TLF (device oriented composite endpoint)
when treating bifurcation lesions.





(n = 281) Difference (95% CI) p-value
Age (years) 66.2 ± 9.9 (126) 66.3 ± 9.7 (281) −0.1 [−2.1, 2.0] .93
Male 96.0% (121/126) 92.9% (261/281) 3.1% [−1.4%, 7.7%] .22
Body mass index (kg/m2) 29.4 ± 5.3 (126) 28.8 ± 4.4 (281) 0.7 [−0.3, 1.7] .21
COPD 8.7% (11/126) 11.4% (32/281) −2.7% [−8.8%, 3.5%] .42
Peripheral vascular disease 7.1% (9/126) 7.1% (20/281) 0.0% [−5.4%, 5.4%] .99
Creatinine clearance (mL/min) 83.6 ± 27.4 (126) 82.6 ± 27.4 (281) 1.0 [−4.8, 6.8] .74
LVEF (%) 57.6 ± 7.2 (126) 58.3 ± 8.3 (281) −0.6 [−2.3, 1.0] .46
Current smoker 10.1% (12/119) 16.0% (44/275) −5.9% [−12.8%, 1.0%] .12
Diabetes mellitus Type I or II 27.2% (34/125) 29.7% (83/279) −2.5% [−12.0%, 6.9%] .60
Insulin dependent diabetes 10.4% (13/125) 7.2% (20/279) 3.2% [−2.9%, 9.4%] .27
Oral mediation only 14.4% (18/125) 20.4% (57/279) −6.0% [−13.8%, 1.7%] .15
Diet only 2.4% (3/125) 1.8% (5/279) 0.6% [−2.5%, 3.7%] .71
Hypertension (or on treatment for hypertension) 78.4% (98/125) 75.0% (210/280) 3.4% [−5.4%, 12.2%] .46
Hyperlipidemia (or on treatment for hyperlipidemia) 83.9% (104/124) 73.5% (202/275) 10.4% [2.1%, 18.7%] .023
Medical history
Peripheral vascular disease 7.1% (9/126) 7.1% (20/281) 0.0% [−5.4%, 5.4%] .99
Previous stroke 4.8% (6/126) 5.0% (14/281) −0.2% [−4.7%, 4.3%] .92
Previous MI 14.4% (18/125) 12.1% (34/280) 2.3% [−5.0%, 9.5%] .53
Pulmonary hypertension (moderate/severe) 0.0% (0/113) 0.4% (1/255) −0.4% [−1.2%, 0.4%] 1.00
Anginal status .67
Silent ischemia 3.2% (4/126) 6.0% (17/281)
Stable angina 72.2% (91/126) 69.0% (194/281)
Unstable angina 24.6% (31/126) 24.6% (69/281)
None of the above 0.0% (0/126) 0.4% (1/281)
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Treating bifurcation was historically prone to worst prognosis fol-
lowing PCI.16 For instance, bifurcation lesion is one of the criteria that
increases the anatomical SYNTAX score—a tool that shows the
coronary complexity and that is recommended by Guidelines for deci-
sion making on the most appropriate treatment strategy (PCI or
CABG).17










Anatomical SYNTAX score 21.5 ± 5.7 (126) 19.7 ± 6.5 (281) 1.9 [0.5, 3.2] .006
Syntax score II (for treatment with PCI) 29.8 ± 8.2 (126) 29.7 ± 8.5 (281) 0.1 [−1.6, 1.9] .88
4 year predicted mortality PCI (pct) 8.5 ± 7.6 (126) 8.5 ± 8.6 (281) −0.1 [−1.8, 1.7] .92
Number of assessed lesions (by iFR/FFR) (mean ± SD, N) 3.56 ± 0.93 (126) 3.43 ± 0.98 (281) 0.13 [−0.07, 0.33] .21
Number of assessed segments (by iFR/FFR) (mean ± SD, N) 4.06 ± 1.06 (126) 3.44 ± 0.98 (281) 0.61 [0.40, 0.83] <.001
Number of treated segments (mean ± SD, N) 3.22 ± 1.12 (126) 2.55 ± 1.13 (278) 0.68 [0.44, 0.91] <.001
Chronic total occlusion 31.7% (40/126) 25.6% (72/281) 6.1% [−3.5%, 15.7%] .20
Vessels treated:
RCA 61.1% (77/126) 62.2% (173/278) −1.1% [−11.4%, 9.1%] .83
LAD 99.2% (125/126) 89.2% (248/278) 10.0% [6.0%, 14.0%] <.001
LCX 76.2% (96/126) 63.7% (177/278) 12.5% [3.2%, 21.9%] .013
3VD 43.7% (55/126) 35.6% (99/278) 8.0% [−2.3%, 18.4%] .12
Stent information
Per patient
Total stent length (mean ± SD, N) 109.3 ± 54.54 (126) 87.26 ± 51.02 (277) 22.06 [11.05, 33.08] <.001
Number of stents (mean ± SD, N) 4.33 ± 1.85 (126) 3.57 ± 1.91 (281) 0.77 [0.37, 1.17] <.001
Per lesion
Total stent length (mean ± SD, N) 38.80 ± 23.32 (355) 34.73 ± 22.45 (696) 4.07 [1.16, 6.98] .006
Number of stents (mean ± SD, N) 1.54 ± 0.76 (355) 1.43 ± 0.75 (696) 0.10 [0.01, 0.20] .035
Per segment
Total stent length (mean ± SD, N) 35.41 ± 21.21 (389) 34.68 ± 22.39 (697) 0.73 [−2.00, 3.46] .60
Number of stents (mean ± SD, N) 1.40 ± 0.66 (389) 1.43 ± 0.75 (697) −0.03 [−0.12, 0.06] .52
Per stent
Mode of stenting .001
Direct stenting 8.8% (48/546) 14.5% (145/998) −5.7% [−9.0%, −2.5%]
Predilatation 91.2% (498/546) 85.5% (853/998) 5.7% [2.5%, 9.0%]
Stent length (mm; mean ± SD, N) 25.23 ± 9.28 (546) 24.22 ± 9.13 (998) 1.01 [0.05, 1.97] .039
IVUS postprocedural information (per stent)
Postdilation done based on IVUS findings 46.0% (154/335) 36.8% (269/731) 9.2% [2.8%, 15.6%] .004
Malapposition present 6.0% (20/334) 6.3% (46/731) −0.3% [−3.4%, 2.8%] .85
Minimum stent area (mm2; mean ± SD, N) 6.16 ± 2.33 (315) 6.21 ± 2.31 (680) −0.05 [−0.36, 0.26] .75
Medina type for treated bifurcations only (visual
assessment)
1,1,1 37.2% (54/145) (0/0)
1,1,0 20.0% (29/145) (0/0)
1,0,1 5.5% (8/145) (0/0)
0,1,1 9.0% (13/145) (0/0)
1,0,0 4.1% (6/145) (0/0)
0,1,0 14.5% (21/145) (0/0)
0,0,1 9.7% (14/145) (0/0)
Staged procedure 15% (19/126) 32% (89/281) <.001
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With the development and spread use of the second generation
thin strut drug eluting stents, with better flexibility, conformability
and deliverability, it is thought that PCI in complex scenarios, such
as in bifurcation lesions and three-vessel disease, would have
improved outcomes.18 In addition, the use of intravascular imaging
guidance, such as IVUS is proven to decrease long-term mortality
and also stent thrombosis after bifurcation treatment with drug elut-
ing stents.19 Therefore, it would be reasonable to assume that the
F IGURE 3 Time-to-first event curves for the primary composite endpoint of all-cause death, any stroke, any myocardial infarction or any
revascularization (MACCE); target lesion failure, and the individual nonhierarchical components of the primary endpoint according to the
treatment of bifurcation in the three-vessel disease patients of SYNTAX II [Color figure can be viewed at wileyonlinelibrary.com]
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combination of these techniques in complex three-vessel disease
patients would result in better clinical outcomes following PCI for
bifurcation.
The 5-years follow-up of the LEADERS all-comers randomized
trial, showed a higher composite endpoint of cardiac death, MI, and
clinically indicated target vessel revascularization in patients with at
least one bifurcation lesion, compared with those without bifurca-
tion.16 In a sub-analysis of patients receiving both zotarolimus and
everolimus eluting stents in the RESOLUTE all-comers trial,20 compar-
ing PCI for bifurcation lesions versus nonbifurcation lesions, the inves-
tigators found no difference between the groups with regards to
cardiac death, TLF, major adverse cardiac events, TLR and definite or
probable stent thrombosis. The results of this sub-analysis of the RES-
OLUTE trial are in keeping with our findings; however, even though
the follow-up was the same as in SYNTAX II, some differences must
be acknowledged. In SYNTAX II there was higher anatomical complex-
ity represented by a numerically higher SYNTAX score (21.5 vs. 18.7)
and also less patients treated with a one-stent technique for bifurca-
tion lesions (50% vs. 79.1% in RESOLUTE).
An upfront two-stent technique usually is preferred when both
the side branch and the distal main vessel are severely diseased or
when the angulation between these vessels is high enough to com-
promise the future access to the side branch. Regarding the compari-
son of one- versus planned two-stent technique, it has been
consistently shown that provisional stenting results in better
prognosis,21,22 despite some specific publication showing otherwise.23
Although the 5-years outcomes of the DK-Crush II trial showed
improvement in TLR with the two-stent technique, some differences
from our report must be noted. First, SYNTAX II patients are three-
vessel diseased, thus with higher risk; second, the two-stent tech-
nique in the present report comprised all the available techniques, not
only one protocoled approach, like in DK-Crush. Also, follow-up in the
present analysis is shorter—2 years. Our results show no statistical dif-
ference between one- versus two-stent technique with regards to
MACCE, TLF, or definite stent thrombosis; despite some visual sepa-
ration of the Kaplan–Meier curves in favor of one-stent technique.
Nevertheless, one should bear in mind that this analysis is underpow-
ered, not allowing a definitive conclusion.
4.1 | Limitations
Some limitations to our analysis must be acknowledged. First, this is a
posthoc analysis, thus presenting inherent limitations. Decision on
performing bifurcation treatment technique was left to the discretion
of the operators following protocoled approach and were therefore
not randomized; unmeasured confounders might have played a role
on the outcomes. The relative small sample size might be considered a
limitation; however, with the state-of-the-art approach in three-vessel
disease patients, the number of patients involved is considerable. The
results of the present analysis should thus be considered hypothesis-
generating, and describe associations but not causality.
5 | CONCLUSION
In our substudy, bifurcation treatment in patients with three-vessel
disease undergoing state-of-the-art PCI had similar event rates of
MACCE but was associated with a trend toward higher incidence of
TLF compared with nonbifurcation lesions. This is a substudy, thus
not powered for the current analysis. The findings must be interpreted
as exploratory and hypothesis generating.
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